Untitled Document



BIOGRAPHICAL

Name: Sanja Dacic, M.D., Ph.D.
Business Address: University of Pittsburgh Medical Center
Presbyterian University Hospital
Department of Pathology, Suite C600, Room C608
Pittsburgh, PA  15213
Business Phone: 412-647-8694
Business Fax: 412-647-3455
Email: dacics@upmc.edu
Birth Place: Croatia
Birth Date: 12/07/1966
Citizenship:  Croatia

EDUCATION AND TRAINING

GRADUATE
1985-1990 
University of Zagreb
M.D.,1990  Medicine
School of Medicine
Zagreb, Croatia

POST-GRADUATE
1991-1993 University of Zagreb
M.Sc.,1993 Medicine
School of Medicine
Zagreb, Croatia
Postgraduate Program
in Experimental Pharmacology

1995-1998 University of Zagreb  
Ph.D., 1998 
Biomedicine
School of Medicine
Zagreb, Croatia
Postgraduate Program
in Pathology
Internship Clinical Hospital “Rebro”
Zagreb, Croatia

10/1995-4/1997   
Postdoctoral Fellow (advisor David W. Rowe, M.D.)
Department of Genetics and Developmental Biology
University of Connecticut Health Center,
Farmington, CT

7/1997- 6/2001
Resident, Anatomic and Clinical Pathology
University of Pittsburgh Medical Center
Pittsburgh, PA
Chief Resident in Clinical Pathology
University of Pittsburgh Medical Center
Pittsburgh, PA

7/2001-6/2002  
Fellow, General Surgical Pathology
University of Pittsburgh Medical Center
Pittsburgh, PA

APPOINTMENTS and POSITIONS

1992-9/1995
Department of Pathology
Research Assistant
University of  Zagreb
School of Medicine
Zagreb, Croatia

7/2002- 08/2008  
University of Pittsburgh  
Assistant Professor of Pathology
School of Medicine
Pittsburgh, PA 15213

09/2008-present   
University of Pittsburgh  
Associate Professor of
School of Medicine   
 Pathology
Pittsburgh, PA 15213


Interim Director,
School of Medicine
Molecular Anatomic Pathology
Pittsburgh, PA 15213
Laboratory

2005-present
University of Pittsburgh
Director,
School of Medicine   
FISH  Laboratory
Pittsburgh, PA 15213

CERTIFICATION and LICENSURE

SPECIALTY CERTIFICATION:

American Board of Pathology  June 2002
Anatomic Pathology

MEDICAL LICENSURE:

ECFMG 1996
Croatia Medical License 1992
Pennsylvania State Medical License  
Expires: December, 2012
MD-072759-L

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

United States and Canadian Academy of Pathology 1997 to present
College of American Pathologists 1997 to present
Association for Molecular Pathology 2002 to present
Pulmonary Pathology Society 2002 to present
Eastern Cooperative Oncology Group 2006 to present
International Association for the Study of Lung Cancer 2009 to present
Arthur Purdy Stout Society 2011 to present
American Society for Clinical Pathology 1997 to 2008

HONORS

International Cancer Technology Transfer Fellowship (ICRETT) 1994
International Union Against Cancer (UICC)

American Registry of Pathology/ Armed Forces Institute of Pathology  12/2000
Fellowship in Genitourinary Pathology

Quarterly Award for the best World Wide Web case report  2000
Department of Pathology UPMC Pittsburgh

Pulmonary Pathology Society Award for the best abstract  2003
(Faculty mentor for resident winner, Diana Ionescu, M.D.)

Department of Pathology Research Day Award-Clinical Research Category 2004
(Faculty mentor for 2nd place resident, Diana Ionescu, M.D.) 

Department of Pathology University of California Los Angeles 2010
Daljit S. and Elaine Sarkaria Lecture

Arthur Purdy Stout Society Young Investigator Award 2011 

PUBLICATIONS

Refereed Articles (Published or in press)

1. Pavelic ZP, Li YQ, Stambrook PJ, McDonald JS, Munch-Wikland E, Dacic S, Danilovic Z, Pavelic L, Mugge RE. Overexpression of p53 protein is common in premalignant head and neck lesions. Anticancer  Res 1994; 14(5B):2259-66.

2. Li YQ, Pavelic ZP, Wanf LJ, McDonald JS, Gleich L, Munck-Wikland E, Dacic S, Danilovic Z, Pavelic LJ, Wilson KM, Gluckman JL, Stambrook PJ. Altered p53  in microdissected, metachronous, premalignant and malignant oral lesions from the same patients. J Clin Pathol:Mol Pathol 1995; 48:M269-M272.

3. Seiwerth S, Guglietta A, Pecur L, Grabarevic Z, Dacic S, Hutinec Z. Immunohistochemical testing of a new anti-EGF antibody. Folia Histochem  Cytobiol 1996; 34(1):27-9.

4. Dodig M, Tadic T, Kronenberg MS, Dacic S, Liu YH, Maxson R, Rowe DW, Lichtler AC. Ectopic Msx2 overexpression inhibits and Msx2 antisense stimulates calvarial osteoblast differentiation. Dev Biol 1999; 209:298-307.

5. Weigel TL, Kosco PJ, Dacic S, Yousem SA, Luketich JD. Fluorescence bronchoscopic surveillance in patients with a history of non-small cell lung cancer. Diagnostic and Therapeutic Endoscopy 1999; 6:1-7.

6.  Weigel TL, Yousem SA, Dacic S, Kosco PJ, Siegfried J, Luketich JD. Fluorescence
bronchoscopic surveillance after curative surgical resection for non-small lung
cancer. Ann Surg Oncol 2000; 7(3):176-80.

Dacic S, Colby TV, Yousem SA. Nodular amyloidoma and primary pulmonary lymphoma with amyloid production: a differential diagnostic problem. Mod Pathol 2000; 13(9):934-40.

Weigel T, Kosco PJ, Dacic S, Ginsberg R, Rusch V, Luketich JD. Post operative fluorescence bronchoscopic surveillance in non-small cell lung cancer patients. Ann Thorac Surg  2001; 71(3):967-70.

Dacic S, Kalajzic I, Visnjic D, Lichtler A, Rowe D. Col1A1-driven transgenic markers of osteoblast lineage progression. J Bone Miner Res 2001;16(7):1228-36.

Dacic S, Sasatomi E, Swalsky PA, Finkelstein SD, Yousem SA. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping . Am J Surg Pathol 2002; 26(4):510-6.

Dacic S, Finkelstein SD, Baksh FK, Swalsky PA, Cong WM,  Barnes LE, Yousem SA. Small cell neuroendocrine carcinoma displays unique profiles of tumor suppressor gene loss in relationship to primary site of formation. Hum Pathol  2002; 33(9):927-32.

Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical analysis of cystosarcoma phyllodes: study of 22 cases. Breast J 2002;8(6):376-81.
Yousem SA, Dacic S. Idiopathic bronchiolocentric interstitial pneumonia. Mod Pathol 2002;15:1148-53.

Baksh F, Dacic S, Finkelstein SD, Swalsky PA, Raja S, Sasatomi E, Luketich JD, Fernando HC, Yousem SA. Widespread molecular alterations present in stage I non-small cell lung carcinoma fail to predict recurrence. Mod Pathol 2003;16:28-34.

Dacic S, C. Trusky, A. Bakker, Finkelstein SD, Yousem SA. Genotypic analysis of pulmonary Langerhans’ cell histiocytosis. Hum Path 2003; 34:1345-49.

Dacic S, Finkelstein SD, Sasatomi E, Kim DW, Yousem SA. Comparative genotypic analysis of sclerosing hemangioma of the lung and bronchioloalveolar carcinoma indicates a similar molecular pathogenesis. Arch Path Lab Med 2004;128(8):880-4.

Ionescu DN, Sasatomi E,  Cieply K, Nola M,  Dacic S. Protein  expression and  gene amplification of  epidermal growth factor receptor in thymic epithelial tumors.  Cancer 2005; 103 (3):630-6.

Kim DW, Dacic S, Iacono A, Grgurich W, Yousem SA. Significance of a solitary perivascular mononuclear infiltrate in lung allograft recipients with mild acute cellular rejection. J Heart Lung Transplant 2005;24 (2):152-5.

Dacic S, Finkelstein SD, Yousem SA. Clonal selection of adenocarcinoma of the lung as determined by loss of heterozygosity. Exp Mol Pathol 2005; 78 (2):135-9.

Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol 2005; 18(5); 651-55.

Ionsecu DN, Dacic S. Lung transplant patient with persistent fever. Arch Path Lab Med 2005; 129:e153-4.

Dacic S, Ionescu DN, Finkelstein SD, Yousem SA. Patterns of allelic loss of multiple synchronous adenocarcinomas of the lung. Am J Surg Pathol 2005; 29(7):897-904.

Dacic S, Flanagan M,  Cieply K, Ramalingam RS, Luketich J, Belani C,  Yousem SA. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol 2006;125(6):860-5.

Stabile LP, Lyker JS, Land SR, Dacic S, Siegfried JM.Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006;27(8):1547-55.

Tofovic  SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascular Pharmacology 2006; 45(6):358-67.

Dacic S, D. Lomago, Hunt JL, Sepulveda A, Yousem SA. Microsatellite instability is rare in  lymphoepithelioma-like carcinoma of  the lung.  Am J Clin Pathol 2007;127(2):1-5.

Chiosea S, Jelezcova E, Chandran U, Luo J, Mantha G, Sobol RW, Dacic S. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res  2007; 65(5):2345-50.

Gradowski JF, Mantha GS, Hunt JL, Dacic S. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Diagn Mol  Pathol 2007; 16(2):87-90.

Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, Siegfried JM, Yu J, Zhang L. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by  promoter hypermethylation. Clin Cancer Res 2007; 13(15):4336-4344.

Yue W, Sun QH, Dacic S, Landreneau R, Siegfried JM, Yu J, Zhang, L.  Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008; 29 (1); 84-92.

Rund CR, Moser AJ, Lee KK, Zeh HJ, Teot LA, Dacic S, Krasinskas AM. Array comparative genomic hybridization (aCGH) analysis of solid pseudopapillary neoplasms of the pancreas. Mod Pathol 2008 21(5):559-64.

Striebel JM., Dacic S, Yousem SA. Gross Cystic Disease Fluid Protein – 15 (GCDFP-15) expression in primary lung adenocarcinoma. Am J Surg Pathol 2008; 32(3):426-32.

Chiosea S, Cagle P, Krasinskas A, Zander D, Mitchell K, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008; 21 (6):742-7.

Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, Siegfried JM. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Mol Cancer Ther. 2008 Jul;7(7):1913-22

35. Dacic  S, Kothmaier  H, Land S, Shuai Y , Halbwedl I, Morbini  P, Murer B, Comin CE, 
Galateau-Salle  F, Demirag  F, Zeren  H, Attanoos  R, Gibbs  A, Cagle PT, HH. Prognostic significance of p16/CDKN2a deletion in pleural malignant mesotheliomas. Virchows Arch  2008;453(6):627-35.

36. Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathol. 2009;19(3):439-48

37.Traynor A, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte S, Siegfried JM. Pilot study of Gefitinib and Fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64(1):51-9.

38. Achcar R, Nikiforova M, Dacic S, Nicholson A, Yousem SA. MAML2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol 2009;
40 (6):854-60.

39. Monaco S, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A  comparison of  EGFR and KRAS status in primary and matched metastatic pulmonary adenocarcinoma. Hum Pathol 2010 Jan;41(1):94-102. Epub 2009 Sep 8.

40.Dacic S, Shuai Y, Yousem SA, Ohori NP, Nikiforova MN. Clinico-pathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010 Feb;23(2):159-68;  2009 Oct 23. [Epub ahead of print]

41. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap B Y,. Barletta JA, Stubb H, Law K, Lindeman N, Mark E, Shaw A, Pasi J, Lynch T, Johnson BE, Iafrate AJ, and Chirieac LR. Unique Clinicopathologic features characterize ALK rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009; 15(16):5216-23. Epub 2009 Aug 11

42. Horbinski C, Nikiforova M, Cieply K, Dacic S, Seethala R. The prognostic value of Ki-67, p53, EGFR, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Arch Path Lab Med 2010;134(8):1170-6

43. Krasinskas AM, Bartlett D, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas: correlation  with loss of p16 protein expression and survival. Mod Pathol 2010 Jan 15. [Epub ahead of print]

44. Chiosea S, Shuai Y,  Cieply K, Nikiforova MN,  Dacic S. EGFR FISH positive lung  
adenocarcinoma: incidence of co-existing KRAS and BRAF mutations. Hum Pathol
2010; 41(8):1053-60.

45.  Al-Maghraby HQ, Khalbuss WE, Rao UN, Cieply K, Dacic S, Monaco SE.
Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: Cytomorphology and MDM2 amplification by FISH. Cytojournal 2010; 6:7:5.

46. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the  
MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J Surg
Pathol 2010; 34(8):1106-21.

47. Moschos S J., Jukic D M, Athanassiou C, Bhargava, Dacic S, Wang X, Kuan SF,
Fayewicz SL, Galambos C, Acquafondata  M, Dhir R,  Becker D.  Expression Analysis
of Ubc9, the Single SUMO E2 Conjugating Enzyme, in Normal and Malignant
Tissues. Hum Pathol 2010;  41(9):1286-98

48.Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010; 23(12):1577-82.

49. Argiris A,  Heron DE, Smith R, Kim S, Gibson Michael, Lai S, Branstetter BF, Posluszny D, Wang L, Seethala R, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer J Clin Oncol 2010; 20;28(36):5294-300.

50.Tarhini A, Kotsakis, A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16(23):5900-7.

51. Seethala RR, Cieply K, Barnes EL, Dacic S. Progressive genetic alterations of adenoid cystic carcinoma with high-grade transformation. Arch Pathol Lab Med. 2011;135(1):123-30.

52.Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011;135(1):110-6

53. García JJ,  Hunt JL,  Weinreb I, McHugh JB, Barnes EL, Cieply K, Dacic S, Seethala RR. Fluorescent in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas:  utility as a diagnostic test Hum Pathol 2011 Jul 19

54.Monaco SE, Krasinskas AM, Kamat, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemistry in mesothelial proliferations diagnosed  by surgical pathology and cytology. Am J  Clin Pathol  2011;135(4):619-27

55 Stabile LP, Dacic S, Land SR, Lenzner D, Dhir  R, Aquafondata M, Landreneau  RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor-beta and progesterone receptor expression identifies lung cancer patients with poor outcome.
Clin Cancer Res  2011; 1;17(1):154-64.

56. Tochigi N, Dacic S, Ohori NP. Bronchoscopic and transthoracic cytology and biopsy for pulmonary non-small cell carcinomas:performance characteristics by procedure and tumor type. Diagn Cytopathol. 2011 Feb 13. doi: 10.1002/dc.21588. [Epub ahead of print]

57.Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of lung: a microdissection study of KRAS and EGFR mutational and amplification status in a Western patient population. Am J Clin Pathol 2011; 135(5):983-9.

58. Ocque R, Tochigi N, Ohori PN, Dacic S. Utility of immunohistochemistry and histochemistry in the classification of lung adenocarcinoma and squamous cell carcinoma in cytology specimens. Am J Clin Pathol 2011;135(5):783-9.

59. Bigbee W, Gopalakrishnan P,  Weissfeld J,  Wilson D, Dacic S, Lokshin A, Siegfried  J. A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from High-Risk Individuals Found to be Cancer-Free by CT Screening. J Thoracic Oncol  2012; 7(4):698-708

60. Xue J,  Gochuico B,  Alawad AS, Feghali-Bostwick CA, Noth I,  Nathn S D, Rosen GD,  Rosas IO, Dacic S, Ocak I, Fuhrman CR, Cuenco KT, Smith MA, Jacobs SS, Zeevi, A, Morel PA,  Pilewski JM, Valentine VG, Gibson KF,  Kaminski N, Sciurba FC, Zhang Y, Duncan SR. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 2011 Feb 23; 6(2):e14715

61 Noeln BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Wiessfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE. Serum biomarker profiles as screening tools in lung cancer. Cancer Biomark. 2012 Jan 1;10(1):3-12.

62.Chiosea S, Sherer C, Jelic T, Dacic S. KRAS Mutant allele specific imbalance in lung adenocarcinoma. Mod Pathol 2011;24(12):1571-7.

63Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer A, Liu Y, Dacic S,  Siegfried JM, Dahlberg S, Schiller J, Belinsky SA. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via  Induction of ISG15. Oncogene 2011 Dec 12. doi: 10.1038/onc.2011.577

64.Horbinski C, Hobbs J,  Cieply K,  Dacic S, Hamilton RL. EGFR expression modulates oligodendroglioma behavior. Am J Pathol. 2011 Oct;179(4):1638-44. Epub 2011 Aug 10.

65.Horbinski C, Nikiforova MN, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, Hamilton RL. The Importance of 10q Status in an Outcomes-Based Comparison Between 1p/19q Fluorescence In Situ Hybridization and Polymerase Chain Reaction-Based Microsatellite Loss of Heterozygosity Analysis of Oligodendrogliomas. J Neuropathol Exp Neurol. 2011 Dec 12. [Epub ahead of print]

66.Thunnissen e, Beasley  MB,  Borczuk A, Brambilla E, Chirieac LR,  Dacic S,  Flieder D, Gazdar A,  Geisinger K, Hasleton  P, Ishikawa Y, Kerr KM,  Lantejoul S, Matsuno Y, Minami Y,  Moreira AL, Motoi N,  Nicholson AG, Noguchi M,  Nonaka D, Pelosi G, Petersen  I, Rekhtman N, Roggli V, Travis WD, Tsao  MS, Wistuba I, Xu H, Yatabe  Y, Witte B, DJ Kuik. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012 Jul 20. doi: 10.1038/modpathol.2012.106. [Epub ahead of print]

67. Stabile L., Rothstein ME, Lenzner D, Land SR, Dacic S, Keohavong P, Siegfried JM. Prevention of tobacco carcinogen-induced lung cancer in mice using anti-estrogen. Cancer Res Carcinogenesis. 2012 Aug 2. [Epub ahead of print]

68. Brcic L, Sherer C, Shuai Y, Hornick J, Chirieac LR, Dacic S. Morphologic and clinicopathologic characteristics of lung squamous cell carcinomas expressing SOX2. Am J Clin Pathol (in press)

69.Tochigi N, Attanoos R, Chirieac LR, Allen TC, Cagle TP, Dacic S. P16 deletion in
sarcomatoid tumors of the lung and pleura. Arch Pathol Clin Med (in press)

70Radu OM, Foxwell T, Cieply K, Navina S,  Dacic S, Nason KS, Davison JM.
HER2 amplification in gastroesophageal adenocarcinoma correlation of two antibodies using gastric cancer scoring  criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Path 2012 Apr;137(4):583-94.

71. Chênevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, Shiwarski D, Seethala RR. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012 Mar 30. doi: 10.1038/modpathol.2012.57. [Epub ahead of print

72.Kantartzis SN, Dacic S, Strollo DC.AIRP Best Cases in Radiologic-Pathologic Correlation: Pulmonary Sarcoidosis Complicated by Aspergilloma Formation. Radiographics. 2012 Mar;32(2):469-73.

73.Schneider F, Luvison A, Cieply K, Dacic S. Sox2 in precursor lesions  of lung squamous cell carcinoma. Hum Pathol (in press)

Invited reviews

1. Dacic S., Yousem SA. Histologic classification of chronic interstitial pneumonias. Am J Respir Cell Mol Biol  2003;29(3 Suppl):S5-9.

2. Dacic S. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis. Exp Rev Mol Diagn 2007; 7 (1): 77-86.

3. Dacic S. Preneoplastic lesions of the lung carcinoma. Arch Path Lab Med 2008; 132(7):1073-78.

4. Dacic S. EGFR assays in lung cancer. Adv Anatom Pathol 2008; 15(4):241-7.

5. Dacic S. Minimally invasive adenocarcinoma of the lung. Adv Anatom Pathol 2009;16(3):166-71.

6. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med 2011; 135: 622-629.

7. Dacic S. Common dilemmas in lung cancer staging. Arch Pathol Lab Med 2012 (in press)

Book chapters

1. Dacic S, Hunt JL. Applications to Anatomic Pathology IN: Zander DS, Popper HH, Jagirdar J, Haque AK, Cagle PT (eds).  Molecular Pathology of Lung Diseases.  Springer-Verlag, 2008.

2. Dacic S, Yousem SA.Molecular Pulmonary Pathology IN: Tubbs, Stoler (eds). Foundations in Diagnostic Pathology: Cell and Tissue Based Molecular Diagnostics. Springer-Verlag, 2008

3. Dacic S. Molecular Diagnostics of Pulmonary Neoplasms IN: Cagle, Allen, Beasley (eds). Diagnostic Pulmonary Pathology, 2nd edition. Informa Healthcare USA, Inc. 2008

4. Hunt JL, Dacic S. Applications in Anatomic Pathology IN: Cagle P, Allen T. (eds) Basic Concepts of Molecular Pathology, 1st  edition. Springer-Verlag, 2009.

5. Dacic S. Neuroendocrine neoplasms of the lung IN: Hunt JL (ed). Molecular Pathology of Endocrine Diseases, 1st edition. Springer-Verlag, 2010.

6. Hammar S, Dacic S. Immunohistology of lung and pleural neoplasms IN: Dabbs D (ed). Diagnostic immunohistochemistry, 2nd edition. Churchill Livingstone, 2010.

7. Dacic S. Salivary gland tumors. IN: Flieder D, Hasleton P. (eds). Spencer’s Pulmonary Pathology, 6th edition. Cambridge Press, 2010 (in press)

8. Dacic S. (guest editor). Surgical Pathology Clinics: Current concepts in pulmonary pathology, Elsevier Inc. Philadelphia, 2010

9. Cagle P, Allen T, Dacic S, Beasley MB, Kerr K (eds.) Advances in Surgical Pathology: Lung Cancer, Lippincott, 2011

10. Cagle P, Allen T, Dacic S, Beasley MB, Kerr K (eds.) Molecular Lung Pathology: 2011 (in press)
Published abstracts

1. Dacic S, Rotkvic I, Danilovic Z, Cviko A, Dodig M, Erceg D, Simicevic V, Devcic M. The influence of domperidone and restraint stress on the endocrine pancreas in rats. Pathol Res Pract 189(6-7):683, 1993 Aug, 14th European Congress of Pathology, Innsbruck, Austria.

2.Li YQ, Stambrook PJ, Gluckman JL, Pavelic LJ, Munck-Wikland E, Danilovic Z, Dacic S, Pavelic ZP. p53 mutation and protein overexpression in human squamous cell carcinoma of the head and neck (SCCHN). Pro Am Asso Canc Res 35:3616, 1994 March.

3. Pavelic ZP, Li YQ, Stambrook PJ, Munck-Wikland, Pavelic K, McDonald JS, Dacic S, Danilovic Z, Pavelic L, Mugge RE, Wilson K, Nguyen C, Klusman P, Gluckman JL. p 53 mutation and expression during multistage human head and neck carcinogenesis. Proceedings of the International Cancer Congress: 923-927, 1994, 16th International Cancer Congress, New Delhi, India.

4. Dacic S, Dodig M, McKinstry M, Lichtler A, Rowe D. Transgenes as markers of bone lineage progression. J Bone Min Res 11:S395, August 1996, 18th Annual Meeting of American Society for Bone and Mineral Research, Seattle, WA. 

5.Dacic S, Kounelis S, Kouri E, Jones MW. Immunohistochemical analysis of cystosarcoma phyllodes:study of 22 cases. Am J Clin Path 112:537, October 1999, Fall Meeting  of the ASCP/CAP, New Orleans, LA. 

6. Jones MW, Kounelis S, Dacic S, Kouri E, Hoffner L, Surti U. Analysis of p53 tumor suppressor gene deletions by FISH in cystosarcoma phyllodes of the breast. 5th Annual Multidisciplinary Symposium on Breast Disease, February 2000, Rome, Italy.

7. Weigel TL, Kosco PJ, Ebright MI, Dacic S, Luketich JD, Ginsberg RJ. Surveillance for second primaries with fluorescence bronchoscopy in post-resection non-small cell lung cancer patients. Annual Meeting ASCO,  2000, abstract # 101467.

8.Dacic S, Finkelstein SD, Baksh FK, Swalsky PA, Cong WM, Siva R, Yousem SA. Comparative analysis of small cell neuroendocrine carcinomas arising from lung, head and neck and gastrointestinal tract. Mod Pathol 13(3):208A, 2000, Annual Meeting USCAP, New Orleans, LA.

9. Dacic S, Sasatomi E, Swalsky PA, Bakker A, Wooks J, Finkelstein SD. Multiple divergent tumor cell clones constitute the intraductal, invasive and metastatic components of ductal carcinoma in women under age 40. Mod Pathol 14(1):210A, 2001, Annual Meeting USCAP, Atlanta, GA.

10. Finkelstein SD, Dacic S, Sasatomi E, Swalsky PA, Thompson J, Murphy J, Hunt J. Molecular discrimination of reactive versus neoplastic cellular proliferation. J Mol Diagn 4 (4):254, 2002, Annual Meeting of Association for Molecular Pathology, Dallas, TX.

11. Dacic S, Trusky C, Bakker A, Finkelstein S, Yousem SA. Molecular aberrations in Langerhans cell histiocytosis of the lung. Lab Invest 83(1):306A, 2003, Annual Meeting USCAP, Washington, DC.

12. Ionescu D, Cieply K, Dacic S. EGFR amplification in the thymic epithelial tumors. Lab Invest 83(1):308A, 2003, Annual Meeting USCAP, Washington, DC.

13.Ionescu D, Finkelstein S, Swalsky P, Murphy J, Trusky C, Dacic S. Genotypic analysis distinguishes de novo lung carcinoma from local recurrence/metastasis. Annual Meeting of American Thoracic Society, 2003, Seattle, WA.

14.Dacic S, Ramalingam S, Luketich J, Yousem SA, Belani PC: Fluorescent in situ hybridization (FISH) evaluation of HER-2/neu, and Cyclin D1 expression in non-small cell lung cancer (NSCLC): Correlation with clinical behavior. Annual Meeting of  American Society of Clinical Oncology, 2003, Chicago, IL.

15. Ionescu DN, Lomago D, Swalsky PA, Finkelstein SD, Yousem SA, Dacic S. Molecular analysis of multiple synchronous non-small cell lung carcinomas (NSCLC): impact on staging. Mod Pathol 17(1):337A, 2004, Annual Meeting USCAP, Vancouver, BC, Canada.

16. Dacic S, Ramalingam S, Flanagan M, Cieply K, Luketich JD, Belani CP, Yousem SA. Correlation between Epidermal Growth Factor Receptor (EGFR) protein expression (PE) and gene amplification (GA) In Non-Small Cell Lung Carcinoma (NSCLC). Annual Meeting of  American Society of Clinical Oncology, 2005, Orlando, FL.

17. Dacic S, Murphy J, Hunt JL. Molecular and immunohistochemical analysis of Nm-23 and Kai-1 tumor metastasis suppressor genes in adenocarcinoma of the lung. Mod Pathol 18 (1):309A, 2005, Annual Meeting USCAP, San Antonio, TX.

18.Dacic S, Lomago D, Hunt JL, Sepulveda A, Yousem SA. Microsatellite instability, proliferation and apoptosis in lymphoepithelioma-like carcinoma of the lung. Mod Pathol 18(1):310A, 2005, Annual Meeting USCAP, San Antonio, TX.

19. Mantha GS, Keener J, Dacic S, Hunt JL. Allelic loss of the ST7 tumor suppressor gene in primary epithelial and endothelial tumors. J Mol Diagn 7(5):ST26, 2005, Annual Meeting Association for Molecular Pathology, Scottsdale, AZ.

20Caglar D, Dacic S, Mantha GS, Hunt JL. Performance characteristics for a diagnostic molecular test for EGFR gene mutations, KRAS mutations, and EGFR amplification in lung adenocarcinomas. Mod Pathol 19(1):304A, 2006, Annual Meeting USCAP, Atlanta, GA.

21. Gradowski JF, Mantha GS, Hunt JL, Dacic S. Molecular alterations in atypical adenomatous hyperplasia occurring in benign and cancer-bearing lungs. Mod Pathol 19(1):308A, 2006, Annual Meeting USCAP, Atlanta, GA.

22. Tofovic SP, Zhang X, Feghali-Bostwick C, Dacic S, Petrusevska G. Estrogens Deficiency Exacerbates Bleomycin-Induced Pulmonary Hypertension and Fibrosis. Annual Meeting of American Thoracic Society, 2006, San Diego, CA.

23. Chiosea S, Murphy J, Geeta M, Dhir R, Dacic S. Dicer, an RNase III endonuclease, as a marker of  bronchioloalveolar carcinoma of the lung. CAP Annual Meeting, San Diego,  September 2006.

24. Mantha GS, Barnes LE, Dacic S, Murphy J, Trusky C, Ellis S, Seethala RR. An initial validation of a clinically applicable molecular loss of heterozygosity panel for adjunctive risk stratification of head and neck squamous dysplasia. J Mol Diagnost 8 (5):660, 2006, Annual Meeting Association for Molecular Pathology, Orlando, Florida.

25. Rund CR, Lee K, Zeh H, Cieply K, Dacic S, Krasinskas AM. Array comparative genomic hybridization analysis (aCGH) of solid pseudopapillary tumors of the pancreas. Mod Pathol 20(2):291A,2007, Annual Meeting USCAP, San Diego, CA

26.Kapali M, Dacic S, Esposito N, Mantha G, Jones MW. Molecular Analysis of Simultaneous Adenocarcinomas of the Ovary and Endometrium. Mod Pathol 20(2):203A, 2007, Annual Meeting USCAP, San Diego, CA

27. Zarandona M, Cieply K, Dhir R, Parwani A, Cumbie K, Sherer C, Salvatore J, Gandhi M, Dacic S, Nikiforov YE, Bastacky S. Utility of a Fluorescence in situ hybridization assay for ERG gene disruption in prostate needle biopsies with prostatic adenocarcinoma, prostatic intraepithelial neoplasia and partial glandular atrophy.  Mod Pathol 21 (1):192A, 2008, Annual Meeting USCAP, Denver, CO

28. Kapali M, Cieply C, Chivukula M, Dacic S. Array Comparative Genomic Hybridization (aCGH) detects discriminatory chromosomal abnormalities between primary peritoneal papillary serous carcinoma and ovarian papillary serous carcinomas. Mod Pathol 21 (1):209A, 2008, Annual Meeting USCAP, Denver, CO

29.Horbinski C, Dacic S, Cieply K, Brat DJ, McClendon RE, Chu CT. Chordoid glioma: molecular characterization of four cases. Mod Pathol 21 (1):321A, 2008, Annual Meeting USCAP, Denver, CO

30. Dacic S, Popper HH, Kothmaier H, Halbwedl I, Morbini P, Murer B, Comin CE, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle PT. Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas. Mod Pathol 21 (1):339A, 2008, Annual Meeting USCAP, Denver, CO

31. Kulich SM, Cagle PT, Cozza EM, Land SR,  Lenzner D, Brcic L, Dacic S. Immunohistochemical expression of signaling molecules Erb-B3, MKP-3, and Stat 1 in non-small cell lung carcinoma. Mod Pathol 21 (1):345A, 2008, Annual Meeting USCAP, Denver, CO

32. Garcia JJ, Hunt JL, Weinreb I, McHugh JB, Barnes EL, Cieply K, Dacic S, Seethala RR.  Fluorescent In-Situ Hybridization for Detection of MAML2 Rearrangements in Oncocytic Mucoepidermoid Carcinomas: Utility as a Diagnostic Test. Mod Pathol 22 (1):247A, 2009, Annual Meeting USCAP, Boston, MA

33. Seethala RR, Zhang X, Turner S, Cieply K, Tubbs R, Dacic S, Hunt JL.  Adenosquamous Carcinomas of the Head and Neck: An Analysis of MDM2, p53 Expression and MAML2 Rearrangements. Mod Pathol 22 (1):251A, 2009, Annual Meeting USACP, Boston, MA

34. Allen TC, Cagle PT, Chirieac LR, Dacic S, Zhai Q. S100P Expression in 449 Non-Small Cell Lung Carcinomas (NSCLCs): A Potential Diagnostic and Prognostic Marker. Mod Pathol 22 (1):349A, 2009, Annual Meeting USCAP, Boston, MA

35. Allen TC, Cagle PT, Dacic S, Chirieac LR, Zhai Q. Glypican-3 Preferentially Stains Lung Squamous Cell Carcinomas: A Microarray Study of 479 Non-Small Cell Lung Carcinomas (NSCLCs). Mod Pathol 22 (1):349A, 2009, Annual Meeting USCAP, Boston, MA

 36. Dacic S, Yousem SA, Ohori PN, Nikiforova M. EGFR/KRAS Mutational Profiling of Lung Adenocarcinomas in a Clinical Practice. Mod Pathol 22 (1):352A, 2009, Annual Meeting USCAP, Boston, MA

Dacic S, Chiosea S, Aspden L, Nikiforova MN.  miRNA Expression Profiling of Lung Adenocarcinomas: Correlation with Mutational Status. Mod Pathol 22 (1):352A, 2009, Annual Meeting USCAP, Boston, MA

Rodig SJ, Dacic S, Yeap BY, Barletta JA, Law K, Lindeman N, Iafrate AJ,  Chirieac LR.  Phenotype of Lung Adenocarcinoma with EML-ALK Fusion in the Western Population. Mod Pathol 22 (1):360A, 2009, Annual Meeting USCAP, Boston, MA

Krasinskas AM, Bartlett D, Cieply K, Dacic S.  CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas: Correlation with Loss of p16 Protein Expression and Survival. Mod Pathol 22 (1): 136A, 2009, Annual Meeting USCAP, Boston, MA


Bigbee WL, Gopalakrishnan V, Dacic S, Hauskrecht M, Weissfeld JL, Wilson DO, Siegfried JM, Lokshin AE.A Multiplexed Serum Biomarker Immunoassay Panel Discriminates Clinical Lung Cancer Patients from Cancer-Free High-Risk Subjects in a CT-Screened Cohort. 2010, 101st AACR Annual Meeting, Washington, DC.

Barletta JA, Thunnissen E, Dacic S, Chirieac LR. Reproducibility of a proposed grading system for lung adenocarcinoma and correlation with molecular alterations. Mod Pathol 23 (1): 398A, 2010, Annual Meeting USCAP, Washington, DC 

Garcia JJ, Barnes EL, Cieply K, Dacic S, Jordan RC, Seethala RR.  Utility of MAML2 Rearrangement Detection Using Florescent In-Situ Hybridization To Distinguish Glandular Odontogenic cyst from Central Mucoepidermoid Carcinoma.  Mod Pathol 24 (1): 277A, 2011, Annual Meeting USCAP, San Antonio, TX

Roy S, Sherer C, Cieply K, Dacic S, Seethala R.  A Comparative Analysis of SOX2 Amplification in Squamous Cell Carcinomas of Lungs and Head and Neck.  Mod Pathol 24 (1): 282A, 2011, Annual Meeting USCAP, San Antonio, TX

Chiosea C, Sherer C, Dacic S. KRAS Amplification Is Restricted to KRAS Mutated Lung Adenocarcinomas.  Mod Pathol 24 (1): 406A, 2011, Annual Meeting USCAP, San Antonio, TX

Monaco, SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S, The Diagnostic Utility of p16FISH and GLUT-1 Immunohistochemistry in Mesothelial Proliferations.  Mod Pathol 24 (1): 419A, 2011, Annual Meeting USCAP, San Antonio, TX

Ocque R, Tochigi N, Ohori P, Dacic S.  Utility of Ancillary Studies in the Classification of Lung Adenocarcinoma and Squamous Cell Carcinoma in Cytology Specimens.  Mod Pathol 24 (1): 421A, 2011, Annual Meeting USCAP, San Antonio, TX

E. Thunnissen1, M. Beasly2, A. Borczuk3, E. Brambilla4, L.R. Chirieac5, S. Dacic6, D. Flieder7, A.F. Gazdar8, K. Geisinger9, Y. Ishikawa10, K.M. Kerr11, Y. Minami12, S. Lantejoul4, Y. Matsuno13, A.L. Moreira14, N. Motoi10, A.G. Nicholson15, M. Noguchi16, D. Nonaka17, G. Pelosi18, I. Petersen19, N. Rekhtman17, V.L. Roggli20, W.D. Travis14, M.S. Tsao21, I. Wistuba22, H. Xu2, Y. Yatabe23, D.J. Kuik1 Reproducibility of invasion in pulmonary adenocarcinoma. An international interobserver study. J Thorac Oncol 2011; EO04.05.14 th  World Lung Cancer Conference, Amsterdam, Netherland

Karunamurthy A, Cai G, Dacic S, Khalbuss WE, Pantanowitz L, Monaco SE.  Diagnostic Utility of Endobronchial Ultrasound-Guided Fine-Needle Aspiration (EBUS-FNA): A Review of 593 Cases.  Mod Pathol 25 (1): 94A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.

Mogal AP, Dacic S, Pingpank J, Bartlett D, Krasinskas AM.  Histologic Subtypes and Pathologic Features of Epithelioid Malignant Peritoneal Mesotheliomas.  Mod Pathol 25 (1): 171A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.

Bastaki JM, Purgina BM, Dacic S, Seethala RR.  Primary Signet-Ring Cell (Mucin-Producing) Adenocarcinoma of Minor Salivary Glands: A Clinicopathologic, Immunohistochemical and Molecular Survey.  Mod Pathol 25 (1): 304A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.

Bilodeau EA, Weinreb I, Dacic S, Muller S, Barker B, Seethala RR.  Clear Cell Odontogenic Carcinomas Show EWSR1 Rearrangements: A Novel Finding & Biologic Link to Salivary Clear Cell Carcinomas.  Mod Pathol 25 (1): 305A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.

Schneider F, Sherer C, Cieply K, Dacic S.  SOX2 Amplification in Bronchial Squamous Dysplasia.  Mod Pathol 25 (1): 490A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.

Travis WD, Rekhtman N, Shen R, Yi ES, Aubry MC, Cheney R, Dacic S, Flieder D, Funkhouser W, Illei P, Myers J, Tsao MS, Wilkerson M, Hammerman P, Govindan R, Hayes N, Myerson M.  Molecular Histologic Correlations in the Cancer Genome Atlas (TCGA) Study of Lung Squamous Cell Carcinoma (SQC).  Mod Pathol 25 (1): 491A, 2012, Annual Meeting USCAP, Vancouver, BC, Canada.
 
Other publications

1. Hunt JL, Dacic S, Barnes EL, Bures JC. Encapsulated follicular variant of papillary thyroid carcinoma (Letter). Am J Clin Pathol 2002; October 118 (4):602-3; discussion 605-6.
2. Argiris A, Gadgeel SM,  Dacic S. Subdividing NSCLC: Reflections on the past, present, and future of lung cancer therapy. Oncology 2009; 23 (13):147-8. (invited commentary)
3. Dacic S, Yousem SA. Molecular testing in lung carcinoma: Quo vadis? Am J Clin Pathol  2010 Jul;134(1):7-9. (invited editorial)
4. Cagle PT, Dacic S. Lung cancer and the future of pathology. Arch Pathol Lab Med 2011;135(3):293-5. (invited editorial)
5. Dacic S. An update in molecular diagnostics of solid tumors. Arch Pathol Lab Med 2011 May;135(5):535-6 (editorial)
6. Dacic S. Lung carcinoma morphology or mutational profile - that is the question. Arch Pathol Lab Med 2011; 135(10):1242-3 (invited editorial)

Digital publications

  • Dacic S., Virji MA. (January 1999). Profiles of total CK, CK-MB, and Troponin I in acute myocardial infarction. Clinical Chemistry, an interactive World Wide Web case study, UPMC Department of Pathology.-
  •  Dacic S. (January 2000). 46-year-old HIV-positive man with a destructive palate lesion. Hematopathology, an interactive World Wide Web case study, UPMC Department of Pathology. (Quarterly Award for the best World Wide Web case report by the Department of Pathology UPMC Pittsburgh)
  • Dacic S. (July 2000). 24-year-old man with flu-like symptoms. Autopsy Pathology, an interactive World Wide Web case study, UPMC Department of Pathology.
  • Dacic S., Johnson DR. (September 2000). 53-year-old woman with a parotid gland  mass. Head and Neck Pathology, an interactive World Wide Web case study, UPMC Department of Pathology.
  • Horbinski C., Dacic S. (January 2005). A Caucasian woman in her late 20s with progressive shortness of breath. Pulmonary Pathology, an interactive World Wide Web case study, UPMC Department of Pathology. (Second Place for the best World Wide Web AP case report in 2005 by the Department of Pathology UPMC Pittsburgh)

TEACHING

Laboratory Instructor 1998
Gastrointestinal Pathology Course
University of Pittsburgh School of Medicine

Laboratory Instructor 1999
Pulmonary Pathology Course
University of Pittsburgh School of Medicine

Laboratory Instructor  2000
Hematopathology Course
University of Pittsburgh School of Medicine

Laboratory Instructor 2004
Introductory Pathology Course Cancer Biology
University of Pittsburgh School of Medicine
(MS-1, 20 students, 2 hrs/week/2weeks)

Laboratory Instructor  2006-present
Body Fluid Homeostasis course, renal segment
University of Pittsburgh School of Medicine
(MS-2, 10 students, 2hrs/week/2weeks)

Lecturer 2006-present
Body Fluid Homeostasis course, pulmonary segment
University of Pittsburgh School of Medicine
(MS-2, entire class, 1 hour lecture)

Small group facilitator   2007
Pathobiology Course
University of Pittsburgh School of Medicine
(MS-2, 10 students, 3 hours/week)

Lecturer and Laboratory Instructor 2007
Intersession Course
University of Pittsburgh School of Medicine
(MS-3, entire class, 1 hour lecture); (MS-3, 10 students, 3.5 hours/week);

Small group facilitator   2009-present
Cellular and Pathologic Basis of Disease
University of Pittsburgh School of Medicine
(MS-2, 10 students, 3 hours/week)

FACULTY ADVISOR/MENTOR

Melissa Muniz, Medical Student, Department of Pathology University of Pittsburgh
Summer Fellowship in Pathology (2005)
Anamarija Morovic, MD, University of Zagreb School of Medicine, Observership in  Anatomic Pathology (November, 2005)
Luka Brcic, MD, University of Zagreb School of Medicine, Visiting Fellow in Pulmonary Pathology (July 2007)
Luka Brcic, University of Zagreb School of Medicine, International Union Against Cancer Fellowship Award (February 2011)

COURSES

American Society for  Clinical Pathology

Annual Meeting

Problems in pulmonary pathology –morphologic and molecular approach to improved diagnosis Short Course
Course co-director, Seattle, WA; October 2005, 1.5 hours
Course co-director, Las Vegas, NV; October 2006, 1.5 hours
Course co-director, New Orleans, LO; October 2007, 1.5 hours

Histologic approach to the diagnosis of interstitial lung diseases video tutorial
Tutorial faculty, Seattle, WA; October 2005, 2.0 hours

Histologic approach to the diagnosis of interstitial lung diseases microscopic tutorial
Tutorial faculty, Las Vegas, NV, October 2006, 2.0 hours

United States and Canadian Academy of Pathology

Annual Meeting

Morphologic and molecular approach to diagnostic problems in pulmonary pathology Short Course (4 year schedule)
Course co-director, Atlanta, GA; 2006, 1.5 hours
Course co-director, San Diego, CA, 2007, 1.5 hours
Course co-director, Denver, CO, 2008, 1.5 hours
Course director, Boston, MA, 2009,  3 hours
Common Questions in Thoracic Consultation Practice Short Course (3 year Schedule)
Course co-director, Washington, DC;2010, 1.5 hours
Course co-director, San Antonio, TX; 2011, 1.5 hours
Course co-director, Vancouver, BC; 2012, 1.5 hours

College of American Pathologists

Annual Meeting
Practical approach to mediastinal lesions video tutorial
Tutorial faculty, San Diego, CA, September 2008, 2.0 hours

Common challenges in the classification of interstitial lung diseases
Tutorial faculty, Chicago, IL, September 2010, 3.0 hours
Tutorial faculty, Dallas, TX, September 2011, 3.0 hours

Annual Meeting
Insights and Controversies in Pulmonary Neoplasia
Course Director, Chicago, IL, September 2010, 3.0 hours
Course Director, Dallas, TX, September 2011, 3.0 hours

RESEARCH  

Grant Support

CURRENT

1. Grant number: NIH  (P50 CA90440)
Grant title: SPORE in lung cancer
Principal Investigator: Jill Siegfried, PhD:
Role in Project : Co-principal investigator (Project 1) and Co-director of the Tissue and Blood Bank Core (20% effort) (2.4 calendar months)
Years inclusive: 01/06/01-04/30/2011
Source % amount: $14,899

2. Grant number: SPORE Developmental Grant (P50-CA090440)
Grant title: Laboratory correlative studies to support early-phase clinical trials of targeted agents in lung cancer
Prinicipal Investigator: Pamela Hershberger, PhD
Role in Project: Co-investigator (5% effort) (0.6 calendar months)
Years inclusive: 05/01/09– 04/30/2011
Source % amount: $3,631 (direct costs)

PRIOR

1. Grant number: Magee-Womens Health Foundation Research Fund
Grant title: Molecular characterization of cystosarcoma phyllodes
Principal Investigator: Mirka W. Jones, MD
Role in Project : Co-investigator  (10% effort)
Years inclusive:  7/1998-7/2000
Source % amount: $25,000.00

2. Grant number: LIFE Clinical Research Award Program Olympus America Inc.
Grant title: LIFE®- lung surveillance for second primaries in patients after curative treatment by surgical resection or photodynamic therapy for non-small cell lung cancer
Principal Investigator: Tracey L. Weigel, MD
Role in Project :  Co-investigator 
Years inclusive: 1/1999-2002
Source % amount: $51,279.70

3. Grant number: NIH (R21)
Grant title: Estradiol metabolites for treatment of pulmonary hypertension
Principal Investigator: Stevan Tofovic, MD
Role in Project : Co-investigator (10% effort)
Years inclusive: 12/01/2005-12/31/2007
Source % amount: $15,369.00

4. Grant number: N01-CO-62209
Grant title: Early therapeutics development with phase II emphasis: Univ. of California Davis
Principal Investigator: Chandra P. Belani, MD
Role in Project : Consultant (2% effort)
Years inclusive: 1/1/06 – 12/31/06
Source % amount:  $772.00

5. Grant number: NIH (R21)
Grant title: KRAS mutations in mouse bronchiolar stem cells as biomarkers for lung cancer.
Prinicipal Investigator: Phouthone Keohavong, PhD
Role in Project: Co-PI (5% effort)
Years inclusive: 12/01/08 – 11/30/2009
Source % amount: $3,631 (direct costs)

PENDING

1. Grant number: NIH (RO1)
Grant title: Mediators of Pulmonary Inflammation Activated by the c-Met Pathway.
Prinicipal Investigator: Jill Siegfried, PhD; 
Role in Project: Co-investigator
Years inclusive:  12/01/2010 – 09/30/14
Source % amount: Pending

2. Grant number: NIH (RO1)
Grant title: CYP24 as a Novel Biomarker and Therapeutic Target in Lung Cancer
Prinicipal Investigator: Pamela Hershberger, PhD
Role in Project: Co-investigator (5% effort in year 5)
Years inclusive: 12/01/08 – 11/30/2013
Source % amount: 5% effort in year 5.  This subaccount will not start until 2013  

EDITORIAL BOARDS AND PEER REVIEW 

Deputy Chief Editor    
Archives of Pathology and Laboratory Medicine
2011-present

Academic Section Editor  
Archives of Pathology and Laboratory Medicine
Molecular Pathology 
2006-2011

Editorial Board Member  
Advances in Anatomic Pathology
2010-present
American Journal of Clinical Pathology
2010-present

Ad Hoc Reviewer
Cancer Research, Clinical Cancer Research, British Journal of Cancer, Cancer, Oncogene, Journal of Thoracic Oncology , Modern Pathology, Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, International Journal for Experimental Pathology, Lung Cancer, Cancer Investigation, Human Pathology, American Journal of Pathology , Journal of Molecular Diagnostics, Pathology Research and Practice, Cancer Chemotherapy and Pharmacology, Virchows Archive 

INVITED SPEAKER

2005 Visiting Professor, Department of Pathology, Mayo Clinic, Rochester, MN

2005 Invited Speaker, Spindle cell lesions of the lung and pleura, American Society for Clinical Pathologists, Teleconference

2005 Invited Speaker and Visiting Professor, XXIII Memorial Meeting Sergej Saltykow, Department of Pathology School of Medicine Zagreb, Zagreb, Croatia

2006 Invited Speaker, “Bronchiolocentric/airway centered interstitial pneumonia”, Annual  Meeting International Academy of Pathology, Montreal, Canada

2006 Invited Speaker, “EGFR in lung carcinogenesis”, Annual Meeting American Society for Clinical Pathologist, Las Vegas, NE

2007 Co-Chair, Pulmonary Session, Annual Meeting USCAP, San Diego, CA

2007 Invited Speaker and Chair, Techniques in Pulmonary Pathology Session, 5th Biennial Symposium Pulmonary Pathology Society, Santa Fe, NM

2007 Invited Speaker, “EGFR in lung carcinogenesis”, Annual Meeting American Society for Clinical Pathologist, New Orleans, LO

2008 Invited Speaker, “EGFR assays in lung cancer”, Companion Meeting CAP, USCAP, Denver, CO

2008 Co-Chair, Pulmonary Session, Annual Meeting USCAP, Denver, CO

2008 Invited Speaker, Pittsburgh Pathology Society

2008 Visiting Professor, Department of Pathology Allegheny General, Pittsburgh, PA

2008 Invited Speaker, “Morphologic and molecular approach to lung neoplasia”, New York Pathological  Society-President’s Symposium, New York, NY

2008 Invited Speaker, “Value Added Molecular Diagnostic in Anatomic Pathology: Basic Techniques and Applications”, Annual Meeting College of American Pathologists, San Diego, CA

2008 Invited Speaker, “BAC and minimally invasive BAC”, Annual  Meeting International
Academy of Pathology, Athens, Greece

2008 Visiting Professor, Department of Pathology, Ohio State University, Columbus, OH

2009 Invited Speaker, “Molecular pathologic diagnosis of lung neoplasia”, 6th Biennial Symposium Pulmonary Pathology Society, Portland, OR

2009 Invited Speaker, “The immunohistochemistry-molecular interface: diagnostic, theranostic and genomic applications” Annual Meeting American Society for Clinical Pathologists, Chicago, IL

2010 Visiting Professor, Department of Pathology, Temple University, Philadelphia, PA

2010 Visiting Professor, Department of Pathology, Yale University, New Haven , CT

2010 Invited Speaker, “Molecular advances  in malignant mesotheliomas”, Companion Meeting Pulmonary Pathology Society, USCAP, Washington, DC

2010 Invited Speaker, Atypical mesothelial proliferations of the pleura -H&E and beyond, American Society for Clinical Pathologists, Teleconference

2010 Visiting Professor, Department of Pathology University of California Los Angeles, Los Angeles, CA

2011 Co-Chair, Pulmonary Session, Annual Meeting USCAP, San Antonio, TX

2011 Chair, Case presentations, 7TH Biennial Symposium Pulmonary Pathology Society,   New York, NY

2011 Invited Speaker, IASLC/ATS/ERS classification of lung adenocarcinomas, American Society for Clinical Pathologists, Teleconference

2011 Invited Speaker, “Companion Diagnostics for targeted therapy in cancer”, Annual  Meeting College of American Pathologists, Dallas, TX

2011 Invited Speaker, “Distinction between second primary and metastases”, 14th World Conference on  Lung Cancer, Amsterdam, Netherland

2011 Invited Speaker, “Molecular targets in non-small cell carcinoma- what to come?”, European Congress of Pathology, Helsinki, Finland

2011 Invited Speaker, “Lung morphology or mutational profile-that is the question” 64th Annual Meeting of California Society of Pathology, San Francisco, California

2012 Visiting Professor, University of Texas South Western, Dallas, TX

2012 Invited Speaker, “Dilemmas in lung cancer staging”, Houston Lung Symposium, Houston, TX

2012 Invited Speaker, Ohio State Society of Pathology, Columbus, OH

SERVICES

Ad Hoc Grant Reviewer    
Austrian Science Fund (FWF)
2004
Program Committee  
Pulmonary Pathology Society,
Member, 2004-2006
Member, 2008-2010
Chair, 2010-2012  
Abstract Review Board  
United States and Canadian Academy of Pathology,
Member, 2006-2010

New Member Recruitment
Pulmonary Pathology Society
Committee  
Member, 2006

Abstract  Review Board 
College of American Pathologists
Member, 2007-present

Teleconference Committee  
American Society for Clinical Pathology
Member, 2007-2011

Nominating Committee 
Pulmonary Pathology Society
Member, 2007-2009

Strategic Marketing Committee
Pulmonary Pathology Society
Member, 2008-2009

Admissions Interviewing
University of Pittsburgh School of Medicine,
Committee 
Member, 2009-present

Cancer Human Biobank (caHUB)
National Cancer Institute,
Office of Biorepositories and  
Ad hoc consulting pathologist, 2009-present
Biospecimen  Research (OBBR)

Residency Committee
Department of Pathology University of Pittsburgh,
Member, 2008-2010

Cancer Committee
University of Pittsburgh Medical Center,
Member, 2009-present

Pathology Committee 
International Association for Study of Lung Cancer (IASLC)
Member, 2010- present

Pathology Committee
International Mesothelioma Panel
Member, 2010- present

Education Committee  
United States and Canadian Academy of Pathology
Member, 2011-2015

External Advisory Board  
Congressionally Directed Medical Research Program
(CDMRP) Lung Cancer Research Program (LCRP),
Member, 2011-present

North American Council  
Pulmonary Pathology  Society
2011-present 

Award Committee  
Pulmonary Pathology Society
Member, 2012-2014